公开(公告)号：EP2305716A2

公开(公告)日：2011-04-06

申请号：EP10172437.5

申请日：2005-11-30

申请人： Curagen Corporation ,  Abgenix, Inc.

发明人： Rastelli, Luca ,  Pollack, Vincent A ,  Tse, Kam Fai ,  Klakamp, Scott ,  Foord, Orit ,  Liang, Meina ,  Xiao, Feng ,  Lichensten, Henri ,  Herrmann, John ,  Larochelle, William J. ,  Jeffers, Michael E. ,  Chapoval, Andrei ,  Mezes, Peter ,  Ara, Gulshan ,  Torgov, Michael ,  Karkaria, Cyrus ,  Davagnino, Juan ,  Jia, Xiao-Chi

IPC分类号： C07K16/30

CPC分类号： C07K16/3053 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/3061 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/62 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/94

摘要： The present invention provides fully human lonoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. the present invention futher provides bispecific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.

摘要翻译： 本发明提供了完全与GPNMB结合的人类单克隆抗体及其用途。 提供编码核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列。 本发明还提供了包含抗GPNMB抗体的免疫缀合物和使用这种免疫缀合物的方法。 本发明还提供了包含抗GPNMB抗体组分和抗CD3组分的双特异性抗体，以及使用这种双特异性抗体的方法。

公开(公告)号：EP2305716A3

公开(公告)日：2011-05-25

申请号：EP10172437.5

申请日：2005-11-30

申请人： Curagen Corporation ,  Abgenix, Inc.

发明人： Rastelli, Luca ,  Pollack, Vincent A ,  Tse, Kam Fai ,  Klakamp, Scott ,  Foord, Orit ,  Liang, Meina ,  Xiao, Feng ,  Lichensten, Henri ,  Herrmann, John ,  Larochelle, William J. ,  Jeffers, Michael E. ,  Chapoval, Andrei ,  Mezes, Peter ,  Ara, Gulshan ,  Torgov, Michael ,  Karkaria, Cyrus ,  Davagnino, Juan ,  Jia, Xiao-Chi

IPC分类号： A61K39/395 ,  A61K47/48 ,  A61P35/00 ,  C07K16/30 ,  C07K19/00 ,  C12N1/21 ,  C12N15/13 ,  C12N15/63 ,  C12N5/10 ,  G01N33/574 ,  G01N33/577

CPC分类号： C07K16/3053 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/3061 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/62 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/94

摘要： The present invention provides fully human lonoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. the present invention futher provides bispecific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.

公开(公告)号：EP2548583A3

公开(公告)日：2013-02-27

申请号：EP12174847.9

申请日：2006-11-13

申请人： Curagen Corporation

发明人： Tse, Kam Fai ,  Pollack, Vincent A ,  MacDougall, John ,  Shenoy, Suresh G. ,  Mansfield, Traci ,  Lichenstein, Henri ,  Jeffers, Michael E. ,  LaRochelle, William J.

IPC分类号： A61K51/00 ,  G01N33/53 ,  A61K39/395 ,  C07K16/46 ,  A61K47/48 ,  A61K51/10 ,  C07K16/28 ,  C07K16/30 ,  G01N33/574

CPC分类号： C07K16/18 ,  A61K47/48469 ,  A61K47/48561 ,  A61K47/48607 ,  A61K47/48638 ,  A61K47/48746 ,  A61K47/6825 ,  A61K47/6849 ,  A61K47/6861 ,  A61K47/6869 ,  A61K47/6897 ,  A61K51/1027 ,  A61K51/106 ,  A61K51/1072 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/3038 ,  C07K16/3069 ,  C07K16/42 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/57438 ,  G01N33/57449 ,  G01N2333/705

摘要： The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies for the treatment of cancer (e.g., renal and ovarian cancer). In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 though FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

公开(公告)号：EP2548583A2

公开(公告)日：2013-01-23

申请号：EP12174847.9

申请日：2006-11-13

申请人： Curagen Corporation

发明人： Tse, Kam Fai ,  Pollack, Vincent A ,  MacDougall, John ,  Shenoy, Suresh G. ,  Mansfield, Traci ,  Lichenstein, Henri ,  Jeffers, Michael E. ,  LaRochelle, William J.

IPC分类号： A61K51/00 ,  G01N33/53 ,  A61K39/395 ,  C07K16/46 ,  A61K47/48 ,  A61K51/10 ,  C07K16/28 ,  C07K16/30 ,  G01N33/574

CPC分类号： C07K16/18 ,  A61K47/48469 ,  A61K47/48561 ,  A61K47/48607 ,  A61K47/48638 ,  A61K47/48746 ,  A61K47/6825 ,  A61K47/6849 ,  A61K47/6861 ,  A61K47/6869 ,  A61K47/6897 ,  A61K51/1027 ,  A61K51/106 ,  A61K51/1072 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/3038 ,  C07K16/3069 ,  C07K16/42 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/57438 ,  G01N33/57449 ,  G01N2333/705

摘要： The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies for the treatment of cancer (e.g., renal and ovarian cancer). In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 though FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

摘要翻译： 中描述的发明涉及指向抗原TIM-1抗体和寻求治疗癌症的抗体的用途（E. G.，肾癌和卵巢癌）。 特别地，设置有引导至抗原TIM -1完全人单克隆抗体。 分离的多核苷酸序列编码，和氨基酸序列，其包含重链和轻链免疫球蛋白分子，特别是序列对应于连续的重链和轻链序列跨越构架区（FR'S）和/或互补性决定区（CDR'S），具体地从FR1虽然FR4 或CDR1到CDR3，提供。 检验的杂交瘤或表达免疫球蛋白分子的其它细胞系和单克隆抗体因此提供。